Skip to main content
Fig. 2 | BMC Urology

Fig. 2

From: Changes in prostate cancer survival among insured patients in relation to USPSTF screening recommendations

Fig. 2

A 3-year prostate cancer-specific survival of insured patients with localized prostate cancer in 2010–2012 (pre-USPSTF era) and 2014–2016 (post-USPSTF era). B 3-year prostate cancer-specific survival of Medicaid patients with localized prostate cancer in 2010–2012 (pre-USPSTF era) and 2014–2016 (post-USPSTF era). C 3-year prostate cancer-specific survival of uninsured patients with localized prostate cancer in 2010–2012 (pre-USPSTF era) and 2014–2016 (post-USPSTF era). D 3-year prostate cancer-specific survival of insured patients with regional prostate cancer in 2010–2012 (pre-USPSTF era) and 2014–2016 (post-USPSTF era). E 3-year prostate cancer-specific survival of Medicaid patients with regional prostate cancer in 2010–2012 (pre-USPSTF era) and 2014–2016 (post-USPSTF era). F 3-year prostate cancer-specific survival of uninsured patients with regional prostate cancer in 2010–2012 (pre-USPSTF era) and 2014–2016 (post-USPSTF era). G 3-year prostate cancer-specific survival of insured patients with metastatic prostate cancer in 2010–2012 (pre-USPSTF era) and 2014–2016 (post-USPSTF era). H 3-year prostate cancer-specific survival of Medicaid patients with metastatic prostate cancer in 2010–2012 (pre-USPSTF era) and 2014–2016 (post-USPSTF era). I 3-year prostate cancer-specific survival of uninsured patients with metastatic prostate cancer in 2010–2012 (pre-USPSTF era) and 2014–2016 (post-USPSTF era). Prostate cancer-specific survival of insured patients across all stages of prostate cancer worsened from 2010–2012 to 2014–2016, while Medicaid and uninsured patients across all stages did not change

Back to article page